FeesSafety
Pluang+

AbbVie offers better value while Eli Lilly leads in growth for 2027 pharma portfolios.

Market News
20 Nov 2026, 18:00 WIB
The Motley Fool
View Source
Bullish
AbbVie offers better value while Eli Lilly leads in growth for 2027 pharma portfolios.

AbbVie and Eli Lilly are key pharmaceutical players with distinct strengths for 2027. AbbVie focuses on immunology and aesthetics with solid cash flow and a lower valuation, making it a value pick. Eli Lilly dominates metabolic health with rapid revenue growth driven by weight-loss and diabetes drugs, representing a high-growth momentum play. Investors face a choice between AbbVie's diversified, cash-rich profile and Lilly's explosive expansion fueled by new treatments. Both have promising pipelines, but AbbVie's lower forward P/E suggests better value for cautious investors in 2027.

As of Nov 20, 2026 23:11 WIB, AbbVie trades at USD 287.66 with a 1-day gain of 1.45% on Pluang, while Eli Lilly is priced at USD 1,356.33, up 0.39% for the day. AbbVie shows a higher dividend yield of 2.47% compared to Eli Lilly's 0.51%, despite Eli Lilly's larger market cap of $1.20 trillion. Notably, Pluang order activity favors selling AbbVie at 95%, contrasting with a more balanced 64% sell and 36% buy split for Eli Lilly.

More News (ABBV)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App